Effects of Ipragliflozin on Diabetic Nephropathy and Blood Pressure in Patients With Type 2 Diabetes: An Open-Label Study

BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors are novel agents used to treat type 2 diabetic patients. We investigated the efficacy of the SGLT2 inhibitor ipragliflozin on diabetic nephropathy in Japanese patients with type 2 diabetes. METHODS: A 50 mg dose of ipragliflozin was admin...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Clin Med Res
Autores principales: Ito, Daisuke, Ikuma-Suwa, Emi, Inoue, Kazuyuki, Kaneko, Kimie, Yanagisawa, Morifumi, Inukai, Kouichi, Noda, Mitsuhiko, Shimada, Akira
Formato: Artigo
Lenguaje:Inglês
Publicado: Elmer Press 2017
Materias:
Original Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5215019/
https://ncbi.nlm.nih.gov/pubmed/28090231
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.14740/jocmr2875w
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares